We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Oncocyte Corporation | NASDAQ:OCX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.06 | 2.17% | 2.82 | 2.77 | 2.98 | 2.98 | 2.71 | 2.71 | 28,786 | 21:30:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction | (Commission | (IRS Employer | ||
of incorporation) | File Number) | Identification No.) |
(Address of principal executive offices)
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Exchange Act:
Title of each class | Trading Symbol | Name of each exchange on which registered | ||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01. Regulation FD Disclosure.
On January 22, 2024, Oncocyte Corporation (the “Company”) made an announcement regarding its VitaGraft Kidney product through a post on its LinkedIn social media account (www.linkedin.com/company/oncocyte-corporation). A copy of the LinkedIn post is furnished as Exhibit 99.1, which, in its entirety, is incorporated herein by reference.
The Company announces material information to the public through a variety of means, including filings with the Securities and Exchange Commission, press releases, public conference calls, the Company’s website (oncocyte.com), its investor relations website (investors.oncocyte.com), and the news releases portion of its website (investors.oncocyte.com/news-releases). The Company uses these channels, as well as social media, including its X account (@OncocyteCorp), Facebook account (www.facebook.com/oncocytecorp) and LinkedIn account (www.linkedin.com/company/oncocyte-corporation), to communicate with investors and the public about the Company, its service offerings, product development efforts, and other matters. Therefore, the Company encourages investors, the media, and others interested in the Company to review the information it makes public in these locations, as such information could be deemed to be material information.
The information in this Current Report on Form 8-K, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. Such information shall not be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as otherwise expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number | Description | |
99.1 | LinkedIn Post dated January 22, 2024 | |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ONCOCYTE CORPORATION | ||
Date: January 23, 2024 | By: | /s/ Joshua Riggs |
Joshua Riggs | ||
President and Chief Executive Officer |
Exhibit 99.1
NOW OFFICIALLY AVAILABLE!!!
We are excited to announce the official launch of #VitaGraft Kidney!
Previously only available through Oncocyte’s Early Access Program, VitaGraft Kidney is now broadly available to transplant professionals upon request.
VitaGraft Kidney is a blood-based test that measures donor-derived cell-free DNA (#dd-cfDNA) concentrations post-kidney #transplantation, serving as an indicator for potential organ damage and rejection.
Also, check out our newly designed VitaGraft Kidney web page!
https://hubs.li/Q02hhzvl0
#OCX #Innovation #WhereTomorrowLives $OCX
We are excited to announce the #OfficialLaunch of #VitaGraft Kidney! Previously only available through Oncocyte’s Early Access Program, VitaGraft Kidney is now broadly available upon request.
#OCX #Innovation #WhereTomorrowLives
Cover |
Jan. 22, 2024 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Jan. 22, 2024 |
Entity File Number | 1-37648 |
Entity Registrant Name | Oncocyte Corporation |
Entity Central Index Key | 0001642380 |
Entity Tax Identification Number | 27-1041563 |
Entity Incorporation, State or Country Code | CA |
Entity Address, Address Line One | 15 Cushing |
Entity Address, City or Town | Irvine |
Entity Address, State or Province | CA |
Entity Address, Postal Zip Code | 92618 |
City Area Code | (949) |
Local Phone Number | 409-7600 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, no par value |
Trading Symbol | OCX |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
1 Year Oncocyte Chart |
1 Month Oncocyte Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions